MARKET

LGND

LGND

Ligand Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

144.73
+9.74
+7.22%
After Hours: 144.20 -0.53 -0.37% 16:34 09/17 EDT
OPEN
135.54
PREV CLOSE
134.99
HIGH
145.36
LOW
134.61
VOLUME
450.88K
TURNOVER
--
52 WEEK HIGH
219.75
52 WEEK LOW
78.26
MARKET CAP
2.41B
P/E (TTM)
52.05
1D
5D
1M
3M
1Y
5Y
Advisors' Inner Circle Fund III Buys Signet Jewelers, Covetrus Inc, Green Plains Inc, Sells ...
GuruFocus News · 09/04 08:38
Why Digital Turbine's Stock Is Trading Higher Today
Digital Turbine Inc (NASDAQ: APPS) is trading higher Tuesday after it was announced the company is set to join the S&P MidCap 400.
Benzinga · 08/31 18:01
Update: Ligand Pharmaceuticals Partner Secures China Approval for Classical Hodgkin's Lymphoma Treatment -- Shares Jump
MT Newswires · 08/31 14:32
Digital Turbine Added To S&P MidCap 400 Index
Benzinga · 08/31 13:21
The Daily Biotech Pulse: VectivBio In M&A Mix, Sonnet Biotherapeutics Advances Candidate To Clinics, CEO Transitions At Galapagos, Talis Biomedical
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 26)
Benzinga · 08/31 12:05
S&P Dow Jones Indices Announces 'Performance Food Group & Digital Turbine Set to Join S&P MidCap 400; TreeHouse Foods & Ligand Pharmaceuticals to Join S&P SmallCap 600'
https://www.spglobal.com/spdji/en/documents/indexnews/announcements/20210830-1442976/1442976_4cbb64core44.pdf
Benzinga · 08/30 21:18
BRIEF-Ligand’S Partner Gloria Biosciences Receives Approval In China For Zimberelimab For The Treatment Of Recurrent Or Refractory Classical Hodgkin’S Lymphoma
reuters.com · 08/30 20:19
Ligand Pharma Partner Gloria Biosciences Receives Approval In China For Zimberelimab For Treatment Of Recurrent, Refractory Classical Hodgkin's Lymphoma
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today announced that its partner Gloria Biosciences (GloriaBio) has received approval from China’s National Medical Products Administration (NMPA) for zimberelimab
Benzinga · 08/30 20:01
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of LGND. Analyze the recent business situations of Ligand Pharma through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 7 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average LGND stock price target is 207.00 with a high estimate of 310.00 and a low estimate of 170.00.
EPS
Institutional Holdings
Institutions: 390
Institutional Holdings: 19.96M
% Owned: 119.68%
Shares Outstanding: 16.68M
TypeInstitutionsShares
Increased
71
1.20M
New
17
209.34K
Decreased
76
678.55K
Sold Out
35
132.07K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.49%
Pharmaceuticals & Medical Research
-0.10%
Key Executives
Non-Executive Chairman/Independent Director
John Kozarich
President/Chief Operating Officer
Matthew Foehr
Chief Executive Officer/Director
John Higgins
Chief Financial Officer/Executive Vice President - Finance
Matthew Korenberg
Senior Vice President/General Counsel/Secretary
Charles Berkman
Independent Director
Jason Aryeh
Independent Director
Sarah Boyce
Independent Director
Jennifer Cochran
Independent Director
Todd Davis
Independent Director
Nancy Gray
Independent Director
John Lamattina
Independent Director
Sunil Patel
Independent Director
Stephen Sabba
Declaration Date
Dividend Per Share
Ex-Div Date
03/20/2007
Dividend USD 2.5
04/03/2007
About LGND
Ligand Pharmaceuticals Incorporated (Ligand) is a biopharmaceutical company that focuses on developing and acquiring technologies that help pharmaceutical companies discover and develop medicines. The Company is involved in the development and licensing of biopharmaceutical assets. The Company employs research technologies, such as nuclear receptor assays, high throughput computer screening, formulation science, liver targeted pro-drug technologies and antibody discovery technologies to assist companies in their work toward obtaining prescription drug approvals. As of December 31, 2016, it had partnerships and license agreements with over 85 pharmaceutical and biotechnology companies, and over 140 various programs under license with it were in various stages of commercialization and development. It has contributed research and technologies for approved medicines that treat cancer, osteoporosis, fungal infections and low blood platelets, among others.

Webull offers kinds of Ligand Pharmaceuticals Inc. stock information, including NASDAQ:LGND real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LGND stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading LGND stock methods without spending real money on the virtual paper trading platform.